Pontifax Overview
Pontifax is a healthcare-focused venture capital firm seeking transformative, cutting-edge life-sciences technologies in all therapeutic areas and development stages. Its portfolio comprises approximately 80 companies developing breakthrough solutions for significant unmet needs. Pontifax invests in breakthrough innovation regardless of therapeutic area or development stage. It establishes its own companies and partners with existing management to nurture start-ups to maturity. Pontifax takes a hands-on approach in its portfolio management and is deeply involved in charting the course of each company. Pontifax began with the vision of its co-founder and chairman, Eli Hurvitz, the CEO and chairman of Teva Pharmaceuticals.
Latest News
growth-positive
Due to high demand for biotech, Pontifax crosses $1.3 billion funding threshold
Israeli biotechnology fund, Pontifax Venture Capital, raised $74 million for its sixth equity fund, bringing its total funds to $404 million. Half of the funds came from existing Israeli institutional investors, while the other half came from American and Chinese entities. The fund focuses on locating biotech companies, importing foreign technologies to Israel, and investing in private and public pharmaceutical companies in the U.S. Pontifax has launched 26 companies and invested in 75 companies. Recent successful exits include Karus Therapeutics and Novellus Dx. Ltd.
Investment
growth-positive
Life Science Investment Firm Pontifax Raises $170 Million Fund
Israel-based venture capital firm Pontifax Ltd. has raised a new $170 million fund focused on credit loans to pharmaceutical companies planning to go public. This is Pontifaxs sixth fund, and it has already begun negotiating investments in five companies. Pontifax has over $600 million in assets under management and has made over 80 investments. The firm has partnerships with leading pharmaceutical and medtech companies, including F. Hoffmann-La Roche AG, Pfizer Inc., Fosun Pharma, and GE Healthcare.
InvestmentExpand
growth-positive
Pontifax Raises a $240 Million Fifth Fund
Israel-based venture capital firm Pontifax raised a fifth fund of $240 million, with most of the money expected to be invested in the pharmaceutical industry. The fund closed within two months due to excess demand. Pontifaxs fourth fund yielded returns of 41%. The firm has partnerships with companies such as F. Hoffmann-La Roche, Pfizer, Fosun Pharma, and GE Healthcare. Pontifax was one of the early investors in Kite Pharma, which was sold to Gilead Sciences for $11.9 billion. Pontifaxs portfolio includes 60 companies, with ten listed on Nasdaq. The firm also plans to launch a biotech incubator in Israel in partnership with Merck Serono and WuXi AppTec Group.
Investment
growth-positive
Pontifax first fund earns 37% return
Healthcare venture capital fund management company Pontifax is likely to raise its fourth fund next year. Pontifax has achieved good returns on its previous funds and has invested in a variety of private companies that recently held Nasdaq IPOs. Pontifax also announced its cooperation with Chinese R&D and initial production company WuXi. At a recent investors conference, Pontifax presented new companies it has invested in, including Quiet Therapeutics and Eloxx Pharmaceuticals. Quiet Therapeutics has developed a drug delivery system that can target malignant tumors, while Eloxx Pharmaceuticals is developing drugs for treating congenital genetic diseases. Pontifax also holds a stake in mobile health company Sweetch, which aims to avert the development of diabetes in patients.
InvestmentExpand
Team Members
9
Web & Social Links
| Website | www.pontifax.com/ |
Locations
Arieh Shenkar Street 14, Herzliya, Israel
Marfin Popular Bank, 12 Hay Hill, London W1J 8NR, UK
Photos & Videos
No files yet
Pontifax Business
Business models
—
Product stage
—
Employees
—
Sector
—Target Customer
—Core Technology
—Tags (6)
e-healthhealthcaremedical-devicesdigital-healthcarebiopharmaceuticallife-sciencesPontifax Financials
—
Total funding
—
Capital raised
—
Last funding
—
Funding stage
—
Total rounds
—
Investors
Pontifax Lifecycle
Pontifax News
4 articles
growth-positive
Due to high demand for biotech, Pontifax crosses $1.3 billion funding threshold
Israeli biotechnology fund, Pontifax Venture Capital, raised $74 million for its sixth equity fund, bringing its total funds to $404 million. Half of the funds came from existing Israeli institutional investors, while the other half came from American and Chinese entities. The fund focuses on locating biotech companies, importing foreign technologies to Israel, and investing in private and public pharmaceutical companies in the U.S. Pontifax has launched 26 companies and invested in 75 companies. Recent successful exits include Karus Therapeutics and Novellus Dx. Ltd.
Investment
growth-positive
Life Science Investment Firm Pontifax Raises $170 Million Fund
Israel-based venture capital firm Pontifax Ltd. has raised a new $170 million fund focused on credit loans to pharmaceutical companies planning to go public. This is Pontifaxs sixth fund, and it has already begun negotiating investments in five companies. Pontifax has over $600 million in assets under management and has made over 80 investments. The firm has partnerships with leading pharmaceutical and medtech companies, including F. Hoffmann-La Roche AG, Pfizer Inc., Fosun Pharma, and GE Healthcare.
InvestmentExpand
growth-positive
Pontifax Raises a $240 Million Fifth Fund
Israel-based venture capital firm Pontifax raised a fifth fund of $240 million, with most of the money expected to be invested in the pharmaceutical industry. The fund closed within two months due to excess demand. Pontifaxs fourth fund yielded returns of 41%. The firm has partnerships with companies such as F. Hoffmann-La Roche, Pfizer, Fosun Pharma, and GE Healthcare. Pontifax was one of the early investors in Kite Pharma, which was sold to Gilead Sciences for $11.9 billion. Pontifaxs portfolio includes 60 companies, with ten listed on Nasdaq. The firm also plans to launch a biotech incubator in Israel in partnership with Merck Serono and WuXi AppTec Group.
Investment
growth-positive
Pontifax first fund earns 37% return
Healthcare venture capital fund management company Pontifax is likely to raise its fourth fund next year. Pontifax has achieved good returns on its previous funds and has invested in a variety of private companies that recently held Nasdaq IPOs. Pontifax also announced its cooperation with Chinese R&D and initial production company WuXi. At a recent investors conference, Pontifax presented new companies it has invested in, including Quiet Therapeutics and Eloxx Pharmaceuticals. Quiet Therapeutics has developed a drug delivery system that can target malignant tumors, while Eloxx Pharmaceuticals is developing drugs for treating congenital genetic diseases. Pontifax also holds a stake in mobile health company Sweetch, which aims to avert the development of diabetes in patients.
InvestmentExpand
Pontifax Team
Tomer Kariv
Co-Founder & CEO
Founder
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
Pontifax Internal
Recent Updates
Matan Eblagon
· matane@sncentral.org · Manual · 2025-06-18 16:01:15.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-11-23 16:06:11.000000
Matan Eblagon
· matane@sncentral.org · Automatic · 2025-01-26 14:39:41.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-11-23 16:14:11.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2025-06-18 16:01:17.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2025-06-18 16:06:31.000000
Matan Eblagon
· matane@sncentral.org · Automatic · 2025-06-18 16:01:17.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-11-23 16:12:28.000000
Inbal Asher
· inbal.taitra@gmail.com · Automatic · 2023-03-21 13:06:18.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2025-06-18 16:06:30.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2025-06-18 16:01:17.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-11-23 15:53:26.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-11-23 16:15:36.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-11-23 16:12:02.000000
Matan Eblagon
· matane@sncentral.org · Automatic · 2025-01-26 14:39:41.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2025-06-18 16:01:16.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-11-23 16:15:36.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-11-23 15:53:55.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-11-23 16:06:11.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-11-23 16:07:19.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-11-23 16:07:19.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-11-23 16:06:22.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2025-06-18 16:06:31.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2025-06-18 16:06:29.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-11-23 16:14:20.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2025-06-18 16:01:15.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-11-23 16:36:09.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-11-23 16:14:42.000000
Matan Eblagon
· matane@sncentral.org · Manual · 2025-06-18 16:06:29.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-11-23 16:12:15.000000
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 55/100 |
| Missing | product stage, sector, number of employees, business model, tag line, video or image, funding rounds, markets, not claimed |
| BI Verification | Jenny Sotnik-Talisman |
| Registrar ID | 515297950 |
| Crunchbase | pontifax |
| Phone | +972-73-7073771 |
| Last updater | Ortal Wein |
| Updater email | ortalw@sncentral.org |
| Last update | 2022-11-23T00:00:00.000Z |
| Created | 2016-02-29T00:00:00.000Z |